Neuren Pharmaceuticals Limited Stock Operating Margin
| NURPF Stock | USD 12.68 0.17 1.36% |
Neuren Pharmaceuticals Limited fundamentals help investors to digest information that contributes to Neuren Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Neuren Pink Sheet. The fundamental analysis module provides a way to measure Neuren Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Neuren Pharmaceuticals pink sheet.
Neuren |
Neuren Pharmaceuticals Limited Company Operating Margin Analysis
Neuren Pharmaceuticals' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Neuren Pharmaceuticals Operating Margin | (2.31) % |
Most of Neuren Pharmaceuticals' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neuren Pharmaceuticals Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, Neuren Pharmaceuticals Limited has an Operating Margin of -2.3059%. This is 93.43% lower than that of the Healthcare sector and 97.94% lower than that of the Biotechnology industry. The operating margin for all United States stocks is 58.15% lower than that of the firm.
Neuren Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neuren Pharmaceuticals' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Neuren Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Neuren Pharmaceuticals by comparing valuation metrics of similar companies.Neuren Pharmaceuticals is currently under evaluation in operating margin category among related companies.
Neuren Fundamentals
| Return On Equity | -0.27 | |||
| Return On Asset | -0.17 | |||
| Profit Margin | (2.15) % | |||
| Operating Margin | (2.31) % | |||
| Current Valuation | 602.02 M | |||
| Shares Outstanding | 128.97 M | |||
| Shares Owned By Insiders | 16.48 % | |||
| Shares Owned By Institutions | 9.41 % | |||
| Price To Earning | 49.75 X | |||
| Price To Book | 27.96 X | |||
| Price To Sales | 203.95 X | |||
| Revenue | 3.2 M | |||
| Gross Profit | (6.32 M) | |||
| EBITDA | (11.43 M) | |||
| Net Income | (7.79 M) | |||
| Cash And Equivalents | 31.09 M | |||
| Cash Per Share | 0.25 X | |||
| Current Ratio | 31.54 X | |||
| Book Value Per Share | 0.27 X | |||
| Cash Flow From Operations | (9.97 M) | |||
| Earnings Per Share | (0.05) X | |||
| Number Of Employees | 15 | |||
| Beta | 1.5 | |||
| Market Capitalization | 660.11 M | |||
| Total Asset | 40.06 M | |||
| Retained Earnings | (97 M) | |||
| Working Capital | 7 M | |||
| Current Asset | 9 M | |||
| Current Liabilities | 2 M | |||
| Z Score | -2.8 | |||
| Net Asset | 40.06 M |
About Neuren Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Neuren Pharmaceuticals Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neuren Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neuren Pharmaceuticals Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Neuren Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Neuren Pharmaceuticals' short interest history, or implied volatility extrapolated from Neuren Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neuren Pharmaceuticals Limited. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Complementary Tools for Neuren Pink Sheet analysis
When running Neuren Pharmaceuticals' price analysis, check to measure Neuren Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuren Pharmaceuticals is operating at the current time. Most of Neuren Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Neuren Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuren Pharmaceuticals' price. Additionally, you may evaluate how the addition of Neuren Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |